Novel transcript, antisense to DDHD1 (ENSG00000258985)

ENSG00000258985 is a non-protein-coding RNA gene annotated as "novel transcript, antisense to DDHD1." This transcript is classified as a natural antisense transcript (NAT), meaning it is transcribed from the strand opposite to the DDHD1 coding sequence and overlaps with it. Antisense lncRNAs can play various regulatory roles in gene expression, primarily by modulating the expression of their sense (protein-coding) gene partners through diverse mechanisms. These include altering mRNA stability, splicing, translation, or guiding chromatin modification at the locus[3][7]. Such transcripts are widespread, and their functional importance is well recognized, although most have not been mechanistically characterized in detail. There is currently no direct evidence that ENSG00000258985 itself is a drug target, biomarker, or associated with specific diseases. Its biological effects (if any) are presumed to be exerted through the regulation of DDHD1, a phospholipase involved in lipid metabolism and neurological function[4][8]. There are no drugs known to interact specifically with this antisense transcript, nor associated mechanism-of-action, safety issues, or disease biomarker uses as of the present knowledge base.

Other names

Antisense to DDHD1lncRNA antisense to DDHD1